Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion–Positive Solid Tumors

Neurotrophic tyrosine receptor kinase (NTRK) gene fusions encode oncogenic, chimeric tropomyosin receptor kinase (TRK) proteins. Larotrectinib, an approved TRK inhibitor, is efficacious in locally advanced or metastatic (adv/met) TRK fusion cancer. We evaluated the time from initial diagnosis to loc...

Descripción completa

Detalles Bibliográficos
Autores principales: Bokemeyer, Carsten, Vassal, Gilles, Italiano, Antoine, De La Cuesta, Esther, Hiemeyer, Florian, Fellous, Marc, Marian, Marisca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457788/
https://www.ncbi.nlm.nih.gov/pubmed/34568715
http://dx.doi.org/10.1200/PO.21.00089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457788/
https://www.ncbi.nlm.nih.gov/pubmed/34568715
http://dx.doi.org/10.1200/PO.21.00089

Ejemplares similares